potentially establishing themselves as long-term rivals to Illumina both within China and in other international markets. The NovaSeq X platform represents a significant advancement in sequencing ...

As the cost of sequencing continues to decrease, more researchers and clinicians may be able to incorporate genomic analysis into their work, expanding the overall market for Illumina’s products. The ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow ...

Using single-cell RNA sequencing, we mapped thousands of expression quantitative trait loci in yeast, including a variant in GPA1 that influences gene expression, cell-cycle occupancy, and mating ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.